Role of nanotechnology in delivery of protein and peptide drugs

Current Pharmaceutical Design

Volumn 21, Issue 29, 2015, Pages 4155-4173

  Patil, Sushilkumar ^a   Vhora, Imran ^a   Amrutiya, Jitendra ^a   Lalani, Rohan ^a   Misra, Ambikanandan ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Bioavailability; Immunogenicity; Nanocarrier; Peptides; Proteins; Stability

Indexed keywords

DRUG; PEPTIDE; PEPTIDE DRUG; PROTEIN; PROTEIN DRUG; UNCLASSIFIED DRUG; DRUG CARRIER;

BIOAVAILABILITY; BIOLOGICAL ACTIVITY; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOGENICITY; NANOTECHNOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; SUSTAINED DRUG RELEASE; ANIMAL; IMMUNOLOGY; NANOMEDICINE; PROCEDURES;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; PEPTIDES; PROTEINS;

EID: 84945893726     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150901095722     Document Type: Review

References (255)

1. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008; 7(1): 21-39
2. Blohm D, Bollschweiler C, Hillen H. Pharmaceutical Proteins. Angew Chem Int Ed Engl 1988; 27(2): 207-25
3. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 2014; 13(9): 655-72
4. Levin AM, Weiss GA. Optimizing the affinity and specificity of proteins with molecular display. Mol Biosyst 2006; 2(1): 49-57
5. Johnson IS. Human insulin from recombinant DNA technology. Science 1983; 219(4585): 632-7
6. Yun YR, Jang JH, Jeon E, et al. Administration of growth factors for bone regeneration. Regen Med 2012; 7(3): 369-85
7. Dawson BV, Hadley ME, Kreutzfeld K, et al. Transdermal delivery of a melanotropic peptide hormone analogue. Life Sci 1988; 43(14): 1111-7
8. Veronesi MC, Kubek DJ, Kubek MJ. Intranasal delivery of a thyrotropin- releasing hormone analog attenuates seizures in the amygdala-kindled rat. Epilepsia 2007; 48(12): 2280-86
9. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab 2011; 96(1): 150-8
10. Tang R, Kim CS, Solfiell DJ, et al. Direct delivery of functional proteins and enzymes to the cytosol using nanoparticle-stabilized nanocapsules. ACS Nano 2013; 7(8): 6667-73
11. Gariboldi S, Palazzo M, Zanobbio L, et al. Low dose oral administration of cytokines for treatment of allergic asthma. Pulm Pharmacol Ther 2009; 22(6): 497-510
12. Yu Z, Li J, Zhu J, et al. A synthetic transmembrane segment derived from TRPV4 channel self-assembles into potassium-like channels to regulate vascular smooth muscle cell membrane potential. J Mater Chem B 2014; 2(24): 3809-18
13. Hemsley KM, Luck AJ, Crawley AC, et al. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur J Neurosci 2009; 29(6): 1197-214
14. Frokjaer S, Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov 2005; 4(4): 298-306
15. Brown LR. Commercial challenges of protein drug delivery. Expert Opin Drug Deliv 2005; 2(1): 29-42
16. Cerreto F, Paolicelli P, Cesa S, et al. Solid lipid nanoparticles as effective reservoir systems for long-term preservation of multidose formulations. AAPS PharmSciTech 2013; 14(2): 847-53
17. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine 2010; 6(1): 9-24
18. Ashley JD, Stefanick JF, Schroeder VA, Suckow MA, Kiziltepe T, Bilgicer B. Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo. J Med Chem 2014; 57(12): 5282-92
19. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010; 75(1): 1-18
20. Peptu CA, Ochiuz L, Alupei L, Peptu C, Popa M. Carbohydrate based nanoparticles for drug delivery across biological barriers. J Biomed Nanotechnol 2014; 10(9): 2107-48
21. Li S-D, Huang L. Pharmacokinetics and Biodistribution of Nanoparticles. Mol Pharm 2008; 5(4): 496-504
22. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol 2012; 52: 481-503
23. Barratt G. Colloidal drug carriers: achievements and perspectives. Cell Mol Life Sci 2003; 60(1): 21-37
24. Karra N, Benita S. The ligand nanoparticle conjugation approach for targeted cancer therapy. Curr Drug Metab 2012; 13(1): 22-41
25. Ozgonenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin? Postgrad Med J 2007; 83(977): 159-63
26. Krzywon M, van der Burg T, Fuhr U, Schubert-Zsilavecz M, Abdel- Tawab M. Study on the dosing accuracy of commonly used disposable insulin pens. Diabetes Technol Ther 2012; 14(9): 804-9
27. Kappelgaard AM, Bojesen A, Skydsgaard K, Sjogren I, Laursen T. Liquid growth hormone: preservatives and buffers. Horm Res 2004; 62 Suppl 3: 98-103
28. Hertel SP, Winter G, Friess W. Protein stability in pulmonary drug delivery via nebulization. Adv Drug Deliv Rev 2014 [Epub ahead of print]
29. Florence AT, Attwood D. Physicochemical Principles of Pharmacy. USA: Pharmaceutical Press 2006
30. Carpi F, Smela E. Biomedical Applications of Electroactive Polymer Actuators. USA: Wiley 2009
31. Boulet-Audet M, Byrne B, Kazarian SG. High-Throughput Thermal Stability Analysis of a Monoclonal Antibody by Attenuated Total Reflection FT-IR Spectroscopic Imaging. Anal Chem 2014; 86(19): 9786-93
32. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006; 8(3): E501-7
33. Pinholt C, Hartvig RA, Medlicott NJ, Jorgensen L. The importance of interfaces in protein drug delivery - why is protein adsorption of interest in pharmaceutical formulations? Expert Opin Drug Deliv 2011; 8(7): 949-64
34. Eu B, Cairns A, Ding G, Cao X, Wen ZQ. Direct visualization of protein adsorption to primary containers by gold nanoparticles. J Pharm Sci 2011; 100(5): 1663-70
35. Wu CS, Chen GC. Adsorption of proteins onto glass surfaces and its effect on the intensity of circular dichroism spectra. Anal Biochem 1989; 177(1): 178-82
36. Arai T, Norde W. The behavior of some model proteins at solidliquid interfaces 1. Adsorption from single protein solutions. Colloids Surf 1990; 51(0): 1-15
37. Ludwig DB, Carpenter JF, Hamel JB, Randolph TW. Protein adsorption and excipient effects on kinetic stability of silicone oil emulsions. J Pharm Sci 2010; 99(4): 1721-33
38. Hoehne M, Samuel F, Dong A, et al. Adsorption of monoclonal antibodies to glass microparticles. J Pharm Sci 2011; 100(1): 123-32
39. Moeller EH, Jorgensen L. Alternative routes of administration for systemic delivery of protein pharmaceuticals. Drug Discov Today: Technol 2008; 5(2–3): e89-e94
40. Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv 2013; 4(11): 1443-67
41. R TB, Jeffrey A, Siahaan TJ, Gangwar S, Pauletti GM. Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. Adv Drug Deliv Rev 1997; 27(2-3): 235-56
42. Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) 2008; 3(5): 703-17
43. Kisel MA, Kulik LN, Tsybovsky IS, et al. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int J Pharm 2001; 216(1-2): 105-14
44. Costanzo JA, O'Brien CJ, Tiller K, et al. Conformational stability as a design target to control protein aggregation. Protein Eng Des Sel 2014; 27(5): 157-67
45. Sánchez-Martín MJ, Ramon E, Torrent-Burgués J, Garriga P. Improved conformational stability of the visual G protein-coupled receptor rhodopsin by specific interaction with docosahexaenoic acid phospholipid. ChemBioChem 2013; 14(5): 639-44
46. SolÁ RJ, Griebenow KAI. Effects of Glycosylation on the Stability of Protein Pharmaceuticals. J Pharm Sci 2009; 98(4): 1223-45
47. Pey AL, Rodriguez-Larrea D, Bomke S, et al. Engineering proteins with tunable thermodynamic and kinetic stabilities. Proteins 2008; 71(1): 165-74
48. Balcao VM, Vila MM. Structural and functional stabilization of protein entities: state-of-the-art. Adv Drug Deliv Rev 2014
49. Balcão VM, Oliveira TA, Malcata FX. Stability of a commercial lipase from mucor jav anicus: kinetic modelling Of Ph and temperature dependencies. Biocatal Biotransfor 1998; 16(1): 45-66
50. Kreuter J. Nanoparticulate systems in drug delivery and targeting. J Drug Target 1995; 3(3): 171-73
51. Yoshimoto M, Sakamoto H, Shirakami H. Covalent conjugation of tetrameric bovine liver catalase to liposome membranes for stabilization of the enzyme tertiary and quaternary structures. Colloids Surf B Biointerfaces 2009; 69(2): 281-7
52. Yoshimoto M, Sato M, Yoshimoto N, Nakao K. Liposomal encapsulation of yeast alcohol dehydrogenase with cofactor for stabilization of the enzyme structure and activity. Biotechnol Prog 2008; 24(3): 576-82
53. Morales-Cruz M, Flores-Fernandez GM, Morales-Cruz M, et al. Two-step nanoprecipitation for the production of protein-loaded PLGA nanospheres. Results Pharma Sci 2012; 2: 79-85
54. Bilati U, Allémann E, Doelker E. Strategic approaches for overcoming peptide and protein instability within biodegradable nanoand microparticles. Eur J Pharm Biopharm 2005; 59(3): 375-88
55. Fu K, Klibanov AM, Langer R. Protein stability in controlledrelease systems. Nat Biotechnol 2000; 18(1): 24-5
56. Du X, Song N, Yang Y-W, Wu G, Ma J, Gao H. Reverse micelles based on [small beta]-cyclodextrin-incorporated amphiphilic polyurethane copolymers for protein delivery. Polym Chem 2014; 5(18): 5300-09
57. Lanza R, Langer R, Vacanti JP. Principles of Tissue Engineering. USA: Elsevier Science 2000
58. Yoo HS, Choi HK, Park TG. Protein-fatty acid complex for enhanced loading and stability within biodegradable nanoparticles. J Pharm Sci 2001; 90(2): 194-201
59. Gaudana R, Khurana V, Parenky A, Mitra AK. Encapsulation of protein-polysaccharide HIP complex in polymeric nanoparticles. J Drug Deliv 2011; 2011
60. Gao GH, Park MJ, Li Y, et al. The use of pH-sensitive positively charged polymeric micelles for protein delivery. Biomaterials 2012; 33(35): 9157-64
61. Niu M, Lu Y, Hovgaard L, Wu W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomed 2011; 6: 1155-66
62. Niu M, Tan Y, Guan P, et al. Enhanced oral absorption of insulinloaded liposomes containing bile salts: a mechanistic study. Int J Pharm 2014; 460(1-2): 119-30
63. Li X, Guo S, Zhu C, et al. Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials 2013; 34(37): 9678-87
64. Iwanaga K, Ono S, Narioka K, et al. Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome's surface on the GI transit of insulin. J Pharm Sci 1999; 88(2): 248-52
65. Zhang N, Ping Q, Huang G, Xu W, Cheng Y, Han X. Lectinmodified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 2006; 327(1–2): 153-59
66. Zhang N, Ping QN, Huang GH, Xu WF. Investigation of lectinmodified insulin liposomes as carriers for oral administration. Int J Pharm 2005; 294(1–2): 247-59
67. Zhang X, Qi J, Lu Y, He W, Li X, Wu W. Biotinylated liposomes as potential carriers for the oral delivery of insulin. Nanomedicine 2014; 10(1): 167-76
68. Thirawong N, Thongborisute J, Takeuchi H, Sriamornsak P. Improved intestinal absorption of calcitonin by mucoadhesive delivery of novel pectin-liposome nanocomplexes. J Control Release 2008; 125(3): 236-45
69. Agrawal AK, Harde H, Thanki K, Jain S. Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules 2013; 15(1): 350-60
70. Fernández-Urrusuno R, Calvo P, Remuñán-López C, Vila-Jato J, José Alonso M. Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles. Pharmaceut Res 1999; 16(10): 1576-81
71. Shahnaz G, Vetter A, Barthelmes J, et al. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization. Int J Pharm 2012; 428(1-2): 164-70
72. Makhlof A, Werle M, Tozuka Y, Takeuchi H. Nanoparticles of glycol chitosan and its thiolated derivative significantly improved the pulmonary delivery of calcitonin. Int J Pharm 2010; 397(1-2): 92-5
73. Kumar M, Pandey RS, Patra KC, et al. Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery. Int J Biol Macromol 2013; 61: 189-95
74. Wang S, Jiang T, Ma M, Hu Y, Zhang J. Preparation and evaluation of anti-neuroexcitation peptide (ANEP) loaded N-trimethyl chitosan chloride nanoparticles for brain-targeting. Int J Pharm 2010; 386(1-2): 249-55
75. Sayin B, Somavarapu S, Li XW, et al. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int J Pharm 2008; 363(1-2): 139-48
76. Baudner BC, Verhoef JC, Giuliani MM, et al. Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. J Drug Target 2005; 13(8-9): 489-98
77. Baudner BC, Giuliani MM, Verhoef JC, Rappuoli R, Junginger HE, Giudice GD. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 2003; 21(25-26): 3837-44
78. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release 2005; 102(2): 373-81
79. Sinsuebpol C, Chatchawalsaisin J, Kulvanich P. Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Des Develop Ther 2013; 7: 861-73
80. Chono S, Fukuchi R, Seki T, Morimoto K. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J Control Release 2009; 137(2): 104-09
81. Huang Y-Y, Wang C-H. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006; 113(1): 9-14
82. Bi R, Shao W, Wang Q, Zhang N. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Target 2008; 16(9): 639-48
83. Kaipel M, Wagner A, Wassermann E, et al. Increased biological half-life of aerosolized liposomal recombinant human Cu/Zn superoxide dismutase in pigs. J Aerosol Med Pulm Drug Deliv 2008; 21(3): 281-90
84. Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: A technical note. AAPS PharmSciTech 2005; 6(3): E482-E86
85. Liu J, Gong T, Fu H, et al. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm 2008; 356(1-2): 333-44
86. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin- loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J Pharm 2001; 218(1-2): 75-80
87. Yamamoto H, Hoshina W, Kurashima H, et al. Engineering of poly (DL-lactic-co-glycolic acid) nanocomposite particles for dry powder inhalation dosage forms of insulin with the spray-fluidized bed granulating system. Adv Powder Technol 2007; 18(2): 215-28
88. Van Der Walle C. Peptide and Protein Delivery. USA: Elsevier Science 2011
89. Banga AK. Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems. Second Ed. USA: CRC Press 2005
90. Audus KL, Raub TJ. Biological barriers to protein delivery. USA: Kluwer Academic Pub 1993
91. Cevc G, Gebauer D, Stieber J, Schätzlein A, Blume G. Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim Biophys Acta - Biomembr 1998; 1368(2): 201-15
92. Paul A, Cevc G, Bachhawat BK. Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. Vaccine 1998; 16(2-3): 188-95
93. Paul A, Cevc G, Bachhawat BK. Transdermal immunization with large proteins by means of ultradeformable drug carriers. Eur J Immunol 1995; 25(12): 3521-4
94. Gupta PN, Mishra V, Singh P, et al. Tetanus toxoid-loaded transfersomes for topical immunization. J Pharm Pharmacol 2005; 57(3): 295-301
95. Gupta PN, Mishra V, Rawat A, et al. Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm 2005; 293(1-2): 73-82
96. Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet 2001; 357(9260): 926-9
97. Zahid S, Brownell I. Repairing DNA damage in xeroderma pigmentosum: T4N5 lotion and gene therapy. J Drugs Dermatol 2008; 7(4): 405-8
98. Egbaria K, Ramachandran C, Kittayanond D, Weiner N. Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies. Antimicrob Agents Chemother 1990; 34(1): 107-10
99. Weiner N, Williams N, Birch G, Ramachandran C, Shipman C, Jr., Flynn G. Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model. Antimicrob Agents Chemother 1989; 33(8): 1217-21
100. Malakar J, Sen SO, Nayak AK, Sen KK. Formulation, optimization and evaluation of transferosomal gel for transdermal insulin delivery. Saudi Pharm J 2012; 20(4): 355-63
101. King MJ, Badea I, Solomon J, Kumar P, Gaspar KJ, Foldvari M. Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther 2002; 4(4): 479-88
102. Alcon VL, Baca-Estrada ME, Potter A, Babiuk LA, Kumar P, Foldvari M. Biphasic lipid vesicles as a subcutaneous delivery system for protein antigens and CpG oligonucleotides. Curr Drug Deliv 2006; 3(2): 129-35
103. King M, Kumar P, Michel D, Batta R, Foldvari M. In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application. Eur J Pharm Biopharm 2013; 84(3): 532-9
104. Lindqvist A, Rip J, Gaillard PJ, Bjorkman S, Hammarlund-Udenaes M. Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study. Mol Pharm 2013; 10(5): 1533-41
105. Caban S, Capan Y, Couvreur P, Dalkara T. Preparation and Characterization of Biocompatible Chitosan Nanoparticles for Targeted Brain Delivery of Peptides. In: Skaper SD, Ed. Neurotrophic Factors. Methods in Molecular Biology. USA: Humana Press; 2012; pp. 321-32
106. Kim J-Y, Choi WI, Kim YH, Tae G. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronicbased nano-carrier. Biomaterials 2013; 34(4): 1170-78
107. Reukov V, Maximov V, Vertegel A. Proteins conjugated to poly(butyl cyanoacrylate) nanoparticles as potential neuroprotective agents. Biotechnol Bioeng 2011; 108(2): 243-52
108. Yun X, Maximov VD, Yu J, Zhu H, Vertegel AA, Kindy MS. Nanoparticles for targeted delivery of antioxidant enzymes to the brain after cerebral ischemia and reperfusion injury. J Cereb Blood Flow Metab 2013; 33(4): 583-92
109. Mazza M, Notman R, Anwar J, et al. Nanofiber-Based Delivery of Therapeutic Peptides to the Brain. ACS Nano 2013; 7(2): 1016-26
110. Cortesi R, Argnani R, Esposito E, et al. Cationic liposomes as potential carriers for ocular administration of peptides with antiherpetic activity. Int J Pharm 2006; 317(1): 90-100
111. Lajavardi L, Bochot A, Camelo S, et al. Downregulation of endotoxin- induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes. Invest Ophthalmol Vis Sci 2007; 48(7): 3230-8
112. Yandrapu SK, Upadhyay AK, Petrash JM, Kompella UB. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharm 2013; 10(12): 4676-86
113. Calvo P, Sanchez A, Martinez J, et al. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharmaceut Res 1996; 13(2): 311-5
114. Di Tommaso C, Torriglia A, Furrer P, Behar-Cohen F, Gurny R, Möller M. Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers. Int J Pharm 2011; 416(2): 515-24
115. Li H, Tran VV, Hu Y, Mark Saltzman W, Barnstable CJ, Tombran- Tink J. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp Eye Res 2006; 83(4): 824-33
116. Casadevall N, Mayeux, M. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346(20): 1584-86
117. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346(7): 469-75
118. Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S. Immunogenicity of recombinant DNA human insulin. Diabetologia 1983; 25(6): 465-9
119. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993; 16 (Suppl 3): 155-65
120. Claustrat B, David L, Faure A, Francois R. Development of antihuman chorionic gonadotropin antibodies in patients with hypogonadotropic hypogonadism. A study of four patients. J Clin Endocrinol Metab 1983; 57(5): 1041-7
121. Blumenfeld Z, Frisch L, Conn PM. Gonadotropin-releasing hormone (GnRH) antibodies formation in hypogonadotropic azoospermic men treated with pulsatile GnRH--diagnosis and possible alternative treatment. Fertil Steril 1988; 50(4): 622-9
122. Grauer A, Ziegler R, Raue F. Clinical significance of antibodies against calcitonin. Exp Clin Endocrinol Diabetes 1995; 103(6): 345-51
123. Porter S. Human immune response to recombinant human proteins. J Pharm Sci 2001; 90(1): 1-11
124. Laricchia-Robbio L, Moscato S, Genua A, Liberati AM, Revoltella RP. Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum. J Cell Physiol 1997; 173(2): 219-26
125. Ragnhammar P, Friesen HJ, Frodin JE, et al. Induction of antirecombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 1994; 84(12): 4078-87
126. Miller LL, Korn EL, Stevens DS, et al. Abrogation of the hematological and biological activities of the interleukin-3/granulocytemacrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood 1999; 93(10): 3250-8
127. Eisenberg JD, Aitken ML, Dorkin HL, et al. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr 1997; 131(1 Pt 1): 118-24
128. Briet E, Peters M. The incidence of inhibitors in hemophilia A and the induction of immune tolerance. Adv Exp Med Biol 2001; 489: 89-97
129. Jacquemin MG, Saint-Remy JM. Factor VIII immunogenicity. Haemophilia 1998; 4(4): 552-7
130. Rosenschein U, Lenz R, Radnay J, Ben Tovim T, Rozenszajn LA. Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction. Isr J Med Sci 1991; 27(10): 541-5
131. Fears R, Ferres H, Glasgow E, et al. Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. Br Heart J 1992; 68(2): 167-70
132. Prümmer O. Treatment-induced antibodies to interleukin-2. Biotherapy 1997; 10(1): 15-24
133. Zang YC, Yang D, Hong J, Tejada-Simon MV, Rivera VM, Zhang JZ. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology 2000; 55(3): 397-404
134. Bukowski RM, Olencki T, Gunn H, et al. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings. Clin Cancer Res 1996; 2(2): 347-57
135. Oberg K, Alm G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989; 81(7): 531-5
136. Bonetti P, Diodati G, Drago C, et al. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha. J Hepatol 1994; 20(3): 416-20
137. Fossa SD, Lehne G, Gunderson R, Hjelmaas U, Holdener EE. Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of antibodies. Int J Cancer 1992; 50(6): 868-70
138. Lok AS, Lai CL, Leung EK. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 1990; 12(6): 1266-70
139. McSweeney EN, Giles FJ, Worman CP, et al. Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia. Br J Haematol 1993; 85(1): 77-83
140. Giannelli G, Antonelli G, Fera G, et al. Biological and clinical significance of neutralizing and binding antibodies to interferonalpha (IFN-alpha) during therapy for chronic hepatitis C. Clin Exp Immunol 1994; 97(1): 4-9
141. Antonelli G, Giannelli G, Currenti M, et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. Clin Exp Immunol 1996; 104(3): 384-7
142. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53(3): 457-65
143. Scott DW, De Groot AS. Can we prevent immunogenicity of human protein drugs? Ann Rheum Dis 2010; 69 (Suppl 1): i72-76
144. Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharmaceut Res 1997; 14(10): 1472-8
145. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000; 48(5): 706-12
146. Peng A, Gaitonde P, Kosloski MP, Miclea RD, Varma P, Balu-Iyer SV. Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. J Pharm Sci 2009; 98(12): 4480-4
147. De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 2009; 131(2): 189-201
148. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002; 24(11): 1720-40 ; discussion 19
149. Guidance for Industry - Immunogenicity Assessment for Therapeutic Protein Products, U.S. Department of Health and Human Services, Food and Drug Administration, August 2014
150. Ortac I, Ruff L, Yeh Y, Esener S. Nanoparticle encapsulated Lasparaginase. Blood 2013; 122(21): 2669-69
151. Nucci ML, Olejarczyk J, Abuchowski A. Immunogenicity of polyethylene glycol-modified superoxide dismutase and catalase. J Free Radic Biol Med 1986; 2(5-6): 321-5
152. Fung W-J, Porter, JE, Bailon, P. Strategies for the preparation and characterization of polyethylene glycol (PEG) conjugated pharmaceutical proteins. Polym Preprint 1997; 38: 565-66
153. Peng A, Kosloski MP, Nakamura G, Ding H, Balu-Iyer SV. PEGylation of a factor VIII–phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia a mice. AAPS J 2012; 14(1): 35-42
154. Peng A, Straubinger RM, Balu-Iyer SV. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J 2010; 12(3): 473-81
155. Purohit VS, Balasubramanian SV. Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity. AAPS J 2006; 8(2): E362-70
156. Purohit VS, Ramani K, Sarkar R, Kazazian HH, Jr., Balasubramanian SV. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-Lserine complex. J Biol Chem 2005; 280(18): 17593-600
157. Kemball-Cook G, Barrowcliffe TW. Interaction of factor VIII with phospholipids: role of composition and negative charge. Thromb Res 1992; 67(1): 57-71
158. Demento SL, Cui W, Criscione JM, et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 2012; 33(19): 4957-64
159. Lee Y-R, Lee Y-H, Kim K-H, Im S-A, Lee C-K. Induction of potent antigen-specific cytotoxic T cell response by PLGAnanoparticles containing antigen and TLR agonist. Immune Network 2013; 13(1): 30-33
160. Camacho AI, Irache JM, de Souza J, Sanchez-Gomez S, Gamazo C. Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice. Vaccine 2013; 31(32): 3288-94
161. Slutter B, Bal S, Keijzer C, et al. Nasal vaccination with Ntrimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 2010; 28(38): 6282-91
162. Muttil P, Prego C, Garcia-Contreras L, et al. Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J 2010; 12(3): 330-7
163. Muttil P, Pulliam B, Garcia-Contreras L, et al. Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses. AAPS J 2010; 12(4): 699-707
164. Copland MJ, Baird MA, Rades T, et al. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003; 21(9-10): 883-90
165. Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 2004; 22(19): 2406-12
166. Lutsiak ME, Robinson DR, Coester C, Kwon GS, Samuel J. Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharmaceut Res 2002; 19(10): 1480-7
167. Kanchan V, Panda AK. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 2007; 28(35): 5344-57
168. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 2005; 298(2): 315-22
169. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc Natl Acad Sci USA 2006; 103(13): 4930-4
170. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharmaceut Res 2009; 26(1): 244-9
171. Han R, Zhu J, Yang X, Xu H. Surface modification of poly(D,Llactic- co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrowderived dendritic cells. J Biomed Mater Res A 2011; 96(1): 142-9
172. Kwon YJ, Standley SM, Goh SL, Frechet JM. Enhanced antigen presentation and immunostimulation of dendritic cells using aciddegradable cationic nanoparticles. J Control Release 2005; 105(3): 199-212
173. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348(7): 601-8
174. Franzke A, Peest D, Probst-Kepper M, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 1999; 17(2): 529-33
175. Kim A, Yun MO, Oh YK, Ahn WS, Kim CK. Pharmacodynamics of insulin in polyethylene glycol-coated liposomes. Int J Pharm 1999; 180(1): 75-81
176. Gaspar MM, Perez-Soler R, Cruz ME. Biological characterization of L-asparaginase liposomal formulations. Cancer Chemother Pharmacol 1996; 38(4): 373-7
177. Nandedkar TD, Sagvekar P, Thakur B, et al. Polymeric nanoparticle formulation of octapeptide (NP-OP): in vitro release and in vivo effect in common marmosets, Callithrix jacchus Linn. Indian J Exp Biol 2013; 51(12): 1055-62
178. Okada H, Heya T, Ogawa Y, Shimamoto T. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J Pharmacol Exp Ther 1988; 244(2): 744-50
179. Solaro R, Chiellini F, Battisti A. Targeted delivery of protein drugs by nanocarriers. Materials 2010; 3(3): 1928-80
180. Putney SD, Burke PA. Improving protein therapeutics with sustained- release formulations. Nat Biotechnol 1998; 16(2): 153-57
181. Almeida AJ, Runge S, Müller RH. Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int J Pharm 1997; 149(2): 255-65
182. Reithmeier H, Herrmann J, Göpferich A. Lipid microparticles as a parenteral controlled release device for peptides. J Control Release 2001; 73(2): 339-50
183. Zhang L, Michigan U. Controlled Release of Angiogenic Growth Factors from Poly(lactic-co-glycolic Acid) Implants for Therapeutic Angiogenesis: University of Michigan 2009
184. Olbrich C, Müller R. Enzymatic degradation of SLN—effect of surfactant and surfactant mixtures. Int J Pharm 1999; 180(1): 31-39
185. Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007; 28(5): 869-76
186. Norde W, Zoungrana T. Surface-induced changes in the structure and activity of enzymes physically immobilized at solid/liquid interfaces. Biotechnol Appl Biochem 1998; 28(2): 133-43
187. Fernandez-Lafuente R, Armisén P, Sabuquillo P, Fernández- Lorente G, M. Guisán J. Immobilization of lipases by selective adsorption on hydrophobic supports. Chem Phys Lipid 1998; 93(1–2): 185-97
188. Barrias CC, Martins MCL, Miranda MCS, Barbosa MA. Adsorption of a therapeutic enzyme to self-assembled monolayers: effect of surface chemistry and solution pH on the amount and activity of adsorbed enzyme. Biomaterials 2005; 26(15): 2695-704
189. Jia L, Shen J, Li Z, et al. In vitro and in vivo evaluation of paclitaxel- loaded mesoporous silica nanoparticles with three pore sizes. Int J Pharm 2013; 445(1-2): 12-9
190. Shang L, Nienhaus K, Nienhaus GU. Engineered nanoparticles interacting with cells: size matters. J Nanobiotechnol 2014; 12(5).
191. Azizi M, Farahmandghavi F, Joghataei M, et al. Fabrication of protein-loaded PLGA nanoparticles: effect of selected formulation variables on particle size and release profile. J Polym Res 2013; 20(4): 1-14
192. Rechendorff K, Hovgaard MB, Foss M, Zhdanov V, Besenbacher F. Enhancement of protein adsorption induced by surface roughness. Langmuir 2006; 22(26): 10885-88
193. Lipski AM, Pino CJ, Haselton FR, Chen I-W, Shastri VP. The effect of silica nanoparticle-modified surfaces on cell morphology, cytoskeletal organization and function. Biomaterials 2008; 29(28): 3836-46
194. Niu Y, Yu M, Hartono SB, et al. Nanoparticles mimicking viral surface topography for enhanced cellular delivery. Adv Mater 2013; 25(43): 6233-7
195. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010; 31(13): 3657-66
196. Hsieh DS, Rhine WD, Langer R. Zero-order controlled-release polymer matrices for micro- and macromolecules. J Pharm Sci 1983; 72(1): 17-22
197. Nanda HS, Chen S, Zhang Q, Kawazoe N, Chen G. Collagen scaffolds with controlled insulin release and controlled pore structure for cartilage tissue engineering. BioMed Res Int 2014; 2014: 10
198. Liu J, Gong T, Wang C, Zhong Z, Zhang Z. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholinebased mixed micelles: preparation and characterization. Int J Pharm 2007; 340(1-2): 153-62
199. Liu J, Gong T, Wang C, Zhong Z, Zhang Z. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholinebased mixed micelles: preparation and characterization. Int J Pharm 2007; 340(1): 153-62
200. Battaglia L, Trotta M, Gallarate M, Carlotti ME, Zara GP, Bargoni A. Solid lipid nanoparticles formed by solvent-in-water emulsiondiffusion technique: development and influence on insulin stability. J Microencapsul 2007; 24(7): 672-84
201. Garcia-Fuentes M, Torres D, Alonso MJ. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm 2005; 296(1): 122-32
202. Oh KS, Han SK, Lee HS, et al. Core/shell nanoparticles with lecithin lipid cores for protein delivery. Biomacromolecules 2006; 7(8): 2362-67
203. Katre NV. Liposome-based depot injection technologies. Am J Drug Deliv 2004; 2(4): 213-27
204. Trif M, Roseanu A, Brock JH, Brewer JM. Designing Lipid Nanostructures for Local Delivery of Biologically Active Macromolecules. J Liposome Res 2007; 17(3-4): 237-48
205. Hsieh PCH, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of PDGF-BB for myocardial protection using in jectable self-assembling peptide nanofibers. J Clin Invest 2006; 116(1): 237-48
206. Koutsopoulos S, Unsworth LD, Nagai Y, Zhang S. Controlled release of functional proteins through designer self-assembling peptide nanofiber hydrogel scaffold. Proc Natl Acad Sci USA 2009; 106(12): 4623-28
207. Morales-Cruz M, Figueroa CM, Gonzalez-Robles T, et al. Activation of caspase-dependent apoptosis by intracellular delivery of Cytochrome c-based nanoparticles. J Nanobiotechnol 2014; 12: 33
208. Compte M, Alonso-Camino V, Santos-Valle P, et al. Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system. Gene therapy 2010; 17(6): 745-51
209. Krebsbach PH, Zhang K, Malik AK, Kurachi K. Bone marrow stromal cells as a genetic platformfor systemic delivery of therapeutic proteins in vivo: human Factor IX model. J Gen Med 2003; 5(1): 11-17
210. Gregoriadis G, Putman D, Louis L, Neerunjun D. Comparative effect and fate of non-entrapped and liposome-entrapped neuraminidase injected into rats. Biochem J 1974; 140(2): 323-30
211. Reynolds GD, Baker HJ, Reynolds RH. Enzyme replacement using liposome carriers in feline GM1 gangliosidosis fibroblasts. Nature 1978; 275(5682): 754-55
212. Steger LD, Desnick RJ. Enzyme therapy. VI: Comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes. Biochim Biophys Acta 1977; 464(3): 530-46
213. Aufenvenne K, Larcher F, Hausser I, et al. Topical enzymereplacement therapy restores transglutaminase 1 activity and corrects architecture of transglutaminase-1-deficient skin grafts. Am J Hum Genet 2013; 93(4): 620-30
214. Cohen CM, Weissmann G, Hoffstein S, Awasthi YC, Srivastava SK. Introduction of purified hexosaminidase A into Tay-Sachs leukocytes by means of immunoglobulin-coated liposomes. Biochemistry 1976; 15(2): 452-60
215. Braidman I, Gregoriadis G. Preparation of glucocerebroside betaglucosidase for entrapment in liposomes and treatment of patients with adult Gaucher's disease. Biochem Soc Trans 1976; 4(2): 259-61
216. Gregoriadis G, Neerunjun D, Meade TW, Goolamali SK, Weereratne H, Bull G. Experiences after long-term treatment of a type I Gaucher disease patient with liposome-entrapped glucocerebroside: beta-glucosidase. Birth Defects Orig Artic Ser 1980; 16(1): 383-92
217. Thekkedath R, Koshkaryev A, Torchilin VP. Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher’s cells in vitro. Nanomedicine 2012; 8(7): 1055-65
218. Gregoriadis G, Ryman BE. Lysosomal localization of - fructofuranosidase-containing liposomes injected into rats. Biochem J 1972; 129(1): 123-33
219. Weissmann G, Bloomgarden D, Kaplan R, et al. A general method for the introduction of enzymes, by means of immunoglobulincoated liposomes, into lysosomes of deficient cells. Proc Natl Acad Sci USA 1975; 72(1): 88-92
220. Méndez J, Morales Cruz M, Delgado Y, et al. Delivery of chemically glycosylated cytochrome c immobilized in mesoporous silica nanoparticles induces apoptosis in HeLa cancer cells. Mol Pharm 2013; 11(1): 102-11
221. Morales-Cruz M, Flores-Fernández GM, Morales-Cruz M, et al. Two-step nanoprecipitation for the production of protein-loaded PLGA nanospheres. Results Pharma Sci 2012; 2(0): 79-85
222. Kumar M, Gupta D, Singh G, et al. Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9. Cancer Res 2014; 74(12): 3271-81
223. Jin Q, Cai T, Wang Y, Wang H, Ji J. Light-Responsive Polyion Complex Micelles with Switchable Surface Charge for Efficient Protein Delivery. ACS Macro Lett 2014; 3(7): 679-83
224. Ayame H, Morimoto N, Akiyoshi K. Self-assembled cationic nanogels for intracellular protein delivery. Bioconjug Chem 2008; 19(4): 882-90
225. Ahmed S, Hayashi F, Nagashima T, Matsumura K. Protein cytoplasmic delivery using polyampholyte nanoparticles and freeze concentration. Biomaterials 2014; 35(24): 6508-18
226. Zhang W, Shi X, Huang J, Zhang Y, Wu Z, Xian Y. Bacitracinconjugated superparamagnetic iron oxide nanoparticles: synthesis, characterization and antibacterial activity. ChemPhysChem 2012; 13(14): 3388-96
227. Mei L, Lu Z, Zhang W, et al. Bioconjugated nanoparticles for attachment and penetration into pathogenic bacteria. Biomaterials 2013; 34(38): 10328-37
228. Daull P, Lallemand F, Philips B, Lambert G, Buggage R, Garrigue JS. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. Cornea 2013; 32(3): 345-54
229. Di Tommaso C, Torriglia A, Furrer P, Behar-Cohen F, Gurny R, Moller M. Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers. Int J Pharm 2011; 416(2): 515-24
230. Mondon K, Zeisser-Labouebe M, Gurny R, Moller M. Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: a suitability study. Eur J Pharm Biopharm 2011; 77(1): 56-65
231. Omri A, Suntres ZE, Shek PN. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol 2002; 64(9): 1407-13
232. Li C, Zhang X, Huang X, Wang X, Liao G, Chen Z. Preparation and characterization of flexible nanoliposomes loaded with daptomycin, a novel antibiotic, for topical skin therapy. Int J Nanomed 2013; 8: 1285-92
233. Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv 2012; 2012: 604204
234. Tomlinson S, Taylor PW, Luzio JP. Transfer of phospholipid and protein into the envelope of Gram-negative bacteria by liposome fusion. Biochemistry 1989; 28(21): 8303-11
235. Sekeri-Pataryas KH, Vakirtzi-Lemonias C, Pataryas HA, Legakis JN. Liposomes as carriers of 14C-labelled penicillin and 125Ilabelled albumin through the cell wall of Pseudomonas aeruginosa. Int J Biol Macromol 1985; 7(6): 379-81
236. Insulin in a tablet - why is it so difficult?, Novo Nordisc, http://www.novonordisk.com/about_us/stories/story/insulin-in-atablet.asp, acccessed on 23 Jan 2015., accessed on
237. Davis SN, Geho B, Tate D, et al. The effects of HDV-insulin on carbohydrate metabolism in Type 1 diabetic patients. J Diabetes Complications 2001; 15(5): 227-33
238. Chalasani KB, Russell-Jones GJ, Jain AK, Diwan PV, Jain SK. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release 2007; 122(2): 141-50
239. Midatech and Monosol Rx announce positive phase 1 clinical results for their novel transbuccal oral insulin film product, Monosol Rx, http://www.monosolrx.com/content/media/releases/news _050312.htm, Accessed on 23 Jan 2015
240. Ohyanagi F, Horai T, Sekine I, et al. Safety of BLP25 Liposome Vaccine (L-BLP25) in Japanese Patients with Unresectable Stage III NSCLC after Primary Chemoradiotherapy: Preliminary Results from a Phase I/II Study. Jap J Clin Oncol 2011; 41(5): 718-22
241. Powell E, Chow LQ. BLP-25 liposomal vaccine: a promising potential therapy in non-small-cell lung cancer. Expert Rev Respir Med 2008; 2(1): 37-45
242. D'Acremont V, Herzog C, Genton B. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J Travel Med 2006; 13(2): 78-83
243. Beck BR, Hatz CF, Loutan L, Steffen R. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine. J Travel Med 2004; 11(4): 201-6
244. Skubitz KM, Anderson PM. Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs 2000; 11(7): 555-63
245. Ten RM, Anderson PM, Zein NN, Temesgen Z, Clawson ML, Weiss W. Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol 2002; 2(2-3): 333-44
246. Balcão VM, Mateo C, Fernández-Lafuente R, Malcata FX, Guisán JM. Structural and functional stabilization of L-asparaginase via multisubunit immobilization onto highly activated supports. Biotechnol Prog 2001; 17(3): 537-42
247. Lopez-Marin LM, Tamariz E, Acosta-Torres LS, Castano VM. Therapeutic proteins and nanotechnology: immune response and stealth bioengineered constructs. Curr Drug Metab 2013; 14(5): 531-9
248. Kubelka GS, Kubelka J. Site-specific thermodynamic stability and unfolding of a de novo designed protein structural motif mapped by 13C isotopically edited IR spectroscopy. J Am Chem Soc 2014; 136(16): 6037-48
249. Sanchez-Ruiz JM. Protein kinetic stability. Biophys Chem 2010; 148(1-3): 1-15
250. Han M, Partin AW. Current clinical applications of the (111)Incapromab pendetide scan (ProstaScint® Scan, Cyt-356). Rev Urology 2001; 3(4): 165-71
251. Goldenberg DM, Abdel-Nabi H, Sullivan CL, et al. Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma. Cancer 2000; 89(1): 104-15
252. Öberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol 1996; 7(5): 453-63
253. Hill HD, Mirkin CA. The bio-barcode assay for the detection of protein and nucleic acid targets using DTT-induced ligand exchange. Nat Protoc 2006; 1(1): 324-36
254. Thaxton CS, Elghanian R, Thomas AD, et al. Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci USA 2009; 106(44): 18437-42
255. Georganopoulou DG, Chang L, Nam J-M, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 2005; 102(7): 2273-76.